Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Current Assets (2016 - 2025)

UroGen Pharma's Current Assets history spans 10 years, with the latest figure at $186.0 million for Q4 2025.

  • For Q4 2025, Current Assets fell 32.63% year-over-year to $186.0 million; the TTM value through Dec 2025 reached $186.0 million, down 32.63%, while the annual FY2025 figure was $186.0 million, 32.63% down from the prior year.
  • Current Assets reached $186.0 million in Q4 2025 per URGN's latest filing, up from $168.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $295.1 million in Q3 2024 to a low of $81.3 million in Q2 2023.
  • Average Current Assets over 5 years is $169.4 million, with a median of $164.5 million recorded in 2022.
  • Peak YoY movement for Current Assets: soared 242.99% in 2024, then plummeted 42.88% in 2025.
  • A 5-year view of Current Assets shows it stood at $114.4 million in 2021, then increased by 12.69% to $128.9 million in 2022, then surged by 31.25% to $169.2 million in 2023, then soared by 63.21% to $276.1 million in 2024, then tumbled by 32.63% to $186.0 million in 2025.
  • Per Business Quant, the three most recent readings for URGN's Current Assets are $186.0 million (Q4 2025), $168.5 million (Q3 2025), and $196.9 million (Q2 2025).